Eton Pharmaceuticals’ (ETON) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $70.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group raised their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Finally, Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $71.50.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $50.31 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $56.49 and its two-hundred day moving average price is $41.16. Eton Pharmaceuticals has a 1 year low of $14.27 and a 1 year high of $66.37. The firm has a market capitalization of $1.44 billion, a P/E ratio of 132.39 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The firm had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. As a group, research analysts anticipate that Eton Pharmaceuticals will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other news, Director Paul V. Maier sold 50,000 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the sale, the insider owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 79,166 shares of company stock valued at $4,809,672. Company insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at about $62,000. Toth Financial Advisory Corp boosted its holdings in shares of Eton Pharmaceuticals by 41.7% during the third quarter. Toth Financial Advisory Corp now owns 1,700 shares of the company’s stock worth $88,000 after acquiring an additional 500 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth approximately $2,156,000. HighTower Advisors LLC boosted its holdings in shares of Eton Pharmaceuticals by 187.2% during the second quarter. HighTower Advisors LLC now owns 52,907 shares of the company’s stock worth $1,915,000 after acquiring an additional 34,484 shares during the period. Finally, Sigma Planning Corp acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $1,086,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.